Fig. 4
From: Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease
Two-way sensitivity analyses simultaneously varying (a) patient age and pre-test probability of AD and (b) utility detriment from lumbar puncture and the cost of biomarker analysis. Triangle: base case; White area: Cost saving at willingness-to-pay of 50,000 per QALY gained; Grey area: ICER of 50,000 100,000 per QALY gained; Black area: ICER> 100,000 per QALY gained. AD Alzheimer's disease, ICER Incremental cost-effectiveness ratio, QALY Quality-adjusted life-year